Childhood protein signatures track adult cardiovascular-kidney-metabolic outcomes
Researchers derived blood-protein patterns associated with 25 cardiovascular-kidney-metabolic traits in 273 children and adolescents. The signatures tracked disease-related outcomes in 685 adults from the same community and 28,256 UK Biobank adults. The Nature Metabolism study reports observational associations; it does not provide a ready screening test for an individual child's future disease or establish which proteins are causal.
Science··Midday
Patterns measured in children
Researchers compared 25 cardiovascular-kidney-metabolic traits with circulating proteins in 273 children and adolescents whose average age was 13.1 years; 53 per cent were female. The analysis covered measures related to body composition, blood pressure, blood lipids, liver, kidney and glucose regulation, producing signatures made up of multiple proteins. The work investigates how far biological patterns measurable in childhood overlap with risk characteristics known in adults, rather than diagnosing clinical disease in the children.[1], [2]
Comparison in two adult groups
The protein signatures derived in children were compared first with data from 685 adults in the same border community and then with 28,256 adults in the UK Biobank. Researchers report that the patterns tracked cardiovascular-kidney-metabolic outcomes in adults. Some proteins also shifted in a healthier direction after GLP-1 receptor agonist treatment in adults. That separate analysis did not test medication in children and does not directly show that the childhood signatures can be modified through treatment.[1], [2]
What the findings do not establish
The study is not an outcome trial following the same children for decades to observe their later disease. It establishes associations between patterns seen in child and adult groups, without identifying which proteins cause disease. The signatures therefore cannot yet be treated as a clinical screening tool that reliably calculates one child's future risk. Although the UTHealth release emphasizes that early markers can be detected from age eight, translation into practice would require validation in other populations and prospective follow-up.[1], [2]
